Introduction {#s1}
============

Insomnia is characterized by sustained difficulties in initiating or maintaining sleep and cause significant impairment of daytime functioning (American Academy of Sleep Medicine, [@B2]). Based on the International Classification of Sleep Disorder (ICSD)-3 of the American Academy of Sleep Medicine, chronic insomnia disorder referred to these symptoms that cause clinically significant functional distress or impairment at least three nights per week for at least 3 months, excluding other medical or mental disorders (Morin et al., [@B45]). Insomnia is the most common sleep complaint, about one third general population worldwide experiencing insomnia symptoms accompanied by daytime dysfunction consequences and \~50% of patients having a chronic course (Morin et al., [@B45]; Buysse, [@B6]). Persistent insomnia is associated with depression, anxiety disorders, suicide, drug/alcohol abuse, accidents, and cardiovascular disease (Baglioni et al., [@B5]; Fernandez-Mendoza and Vgontzas, [@B16]). Moreover, insomnia reduces the quality of life of the patients, and results in increasing healthcare cost and utilization (Leger and Bayon, [@B30]). At least 90% of insomnia-related costs are resulted from the work absences and reduced productivity (Daley et al., [@B13]). The treatments of insomnia include pharmacological therapies, psychological and behavioral therapies, and complementary and alternative therapies (CAM) (Krystal, [@B28]). Benzodiazepines, non-benzodiazepine hypnotics and melatonin receptor agonists are the primary pharmacological therapy. Additionally, the melatonin receptor agonist ramelteon, orexin receptor antagonist suvorexant, and the antidepressant doxepin also have FDA approval for insomnia therapy (Asnis et al., [@B4]). However, the limited use of these pharmacological treatments is due to the undesirable side-effects such as performance and memory impairment, residual sedation, falls, undesired behaviors during sleep, somatic symptoms, and drug interactions (Wilt et al., [@B61]). Psychological and behavioral therapies for insomnia are well supported by empirical evidence (Morin et al., [@B44]), but they have remained underutilized because of requirement of significant training and long-term implementation (Trauer et al., [@B57]). Thus, there are rising numbers of insomniac patients who seek to various kinds of CAM around the world.

Traditional Chinese medicine (TCM), as a main part of CAM, includes Chinese herbal medicine (CHM), acupuncture, meditation and massage (Sarris et al., [@B51]; Zhao, [@B71]; Liu et al., [@B38]). A survey in Hong Kong Chinese reported that the most commonly used CAM modalities was CHM (Yeung et al., [@B67]). CHM formulae (Fufang) are a combination of several CHMs according to TCM theory *Jun-Chen-Zuo-Shi*, known as emperor-miniser-assisstant-courier, first recorded by *Huangdi Neijing* (*Inner Canon of the Yellow Emperor*; Fan et al., [@B15]). CHM has been used for treating insomnia in China for thousands of years (Li and Deng, [@B33]), and is still used today, both in China and elsewhere around the world increasingly (Chen et al., [@B9]; Frass et al., [@B17]). *Semen ziziphi spinosae*, spine date seed, suanzaoren (SZR), the dried seed of *Ziziphus jujuba* Mill. var. *spinosa* (Bunge) Hu ex H. F. Chou (Huang et al., [@B24]; Rodríguez and Rodríguez, [@B50]), is one of the most popular CHMs and has a long history of use in Chinese medicine (Yan, [@B63]; Yeh et al., [@B65]; Ni et al., [@B46]; Rodríguez and Rodríguez, [@B50]; Shergis et al., [@B53]; Singh and Zhao, [@B55]). SZR was first recorded in the *Shennong Bencao Jing* (*Shennong\'s Classic of Materia Medica*), the earliest medicine monograph of China written 2500 years ago (Gu, [@B20]). SZR is the most frequently used single herb for treating insomnia (Lei et al., [@B31]). Systematic reviews of CHM for insomnia have demonstrated that SZR is also the most frequently used herb in randomized controlled trials (RCTs) (Yeung et al., [@B66]; Ni et al., [@B46]). Spinosin and jujubosides are the main active compounds of SZR contributing their sedative and hypnotic effects on insomnia (Peng et al., [@B48]; Li et al., [@B35]; Jiang et al., [@B26]). SZR have been widely used in many standard Chinese formulae for insomnia (Li, [@B32]). In particular, SZR decoction is a well-known classic Chinese herbal formula, and has been used for treating insomnia for more than thousand years, first recorded in *Jingui Yaolue* (*Synopsis of Prescriptions of the Golden Chamber*) by Zhang Zhongjing (AD 152-219). Furthermore, modern pharmacological study indicated that SZR plays an essential role to improve sleep in the SZR decoction (Li and Bi, [@B34]). However, our previous systematic review indicated that the current evidence is insufficient to support the routine use of SZR decoction for insomnia because of poor methodological quality of the included studies (Xie et al., [@B62]). In addition, only data from systematic reviews of high-quality RCTs will receive 1a-evidence according to the levels of evidence from the Centre of Evidence-Based Medicine in Oxford (Glasziou et al., [@B19]). Thus, we conduct an updated systematic review of Chinese herbal formulae that contains SZR (FSZR) for insomnia according to the selected high-quality RCTs.

Methods {#s2}
=======

The systematic review and meta-analysis was preformed according to the Preferred Reporting Items in Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher et al., [@B43]).

Database and search strategies
------------------------------

We have electronically searched Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Chinese National Knowledge Infrastructure (CNKI), Wangfang database, Chinese Biomedical Database (CBM), EMBASE and VIP Journals Database from inception to November 2016 by using the following key words: (semen ziziphi spinosae OR ziziphus jujuba OR suan zao ren OR suanzaoren) AND (dyssomnia OR insomnia OR sleep OR sleep disorder OR sleep maintenance OR sleep initiation) AND (randomized controlled trial OR randomized clinical trial OR controlled clinical trial) in English or in Chinese. In addition, we further hand-searched the reference lists from related literature.

Eligibility criteria
--------------------

### Types of studies

RCTs that evaluated the efficacy and safety of FSZR for insomnia were selected, regardless of language, publication status, or population characteristics. Only RCTs with positive for at least 4 out of 7 for the Cochrane risk of bias domains were included in further analyses. Quasi-randomized trials, for example, allocated by medical record number, date of birth, or the order in which participants are included in the study, were excluded.

### Types of participants

All participants with a diagnosis of insomnia by using Chinese classification of mental disorders (CCMD) (Chinese Society of Psychiatry, [@B10], [@B11], [@B12]), or ICSD (American Sleep Disorders Association, [@B3]; American Academy of Sleep Medicine, [@B1], [@B2]), or Guideline for Clinical Trials of New Patent Chinese Medicines (Zheng, [@B72]) were included. Insomnia disorder caused by a co-occurring psychiatric or medical condition, or withdrawal from a drug or substance was excluded.

### Types of interventions

Analyzed interventions in the experimental groups used FSZR, regardless of the dose or the method or the form or the duration. Comparator interventions were given diazepam, placebo or vehicle treatment or basic treatment (i.e., supportive treatment other than diazepam). Studies comparing FSZR with any other TCM agent were excluded.

### Types of outcome measures

The primary outcome measures were Polysomnography (PSG) index and Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., [@B7]) at the end of the treatment course. The secondary outcome measures were clinical effective rate and adverse events. Evaluation standards for clinical efficacy based on Guideline for Clinical Trials of New Patent Chinese Medicines (Zheng, [@B72]) were as follows: (1) clinical recovery: sleep time returned to normal, or the nocturnal sleep time over 6 h, deep sleep, waking up invigorating; (2) markedly effective: significant improvement of sleep, increased at least 3 h of total sleep time; depth of sleep increased; (3) effective: amelioration in symptoms; increased \<3 h of total sleep time; (4) ineffective: no significant improvement of sleep, or deteriorated after treatment.

Study selection and data collection
-----------------------------------

All studies were searched in the electronic databases independently by two authors. The authors filtered the titles and abstracts of retrieved studies for inclusion. The further review was based on going through the full-text and assessing study eligibility. The exclusion reasons have been recorded. A standardized study extraction was based on first author, population characteristics, study design, study inclusion and exclusion criteria, age and disease duration range of participants, intervention details, duration of treatment, outcomes and follow-up time. For the disagreements, we resolved by discussion between the two authors or hold counsel with the third author.

Risk of bias in individual studies
----------------------------------

The criteria recommended by the Cochrane Collaboration (Higgins and Green, [@B23]) were used to assess the risk of bias in the included studies. The score ranged from 0 to 7. Divergences were well settled through consulting with correspondence authors.

Data synthesis and analysis
---------------------------

We performed the statistical analysis on the data by applying the Cochrane Collaboration Review Manager software (RevMan 5.0). Between-study heterogeneity was valued using the chi-square and the *I*^2^ statistic was calculated. The heterogeneity was expected statistically significant if the *P*-values were \<0.05. Presence or absence of significant heterogeneity decided the option of random effects model or fixed effects model. Outcome data were calculated using standardized mean difference (SMD) with 95% confidence interval (CI) for continuous outcomes, and risk ratio (RR) with 95% CI for dichotomous outcomes. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (Schunemann et al., [@B52]) was used to rate the quality of evidence.

Results {#s3}
=======

Study selection
---------------

The search strategy has retrieved 2,561 studies in total, among which 711 were considered duplicates. Of the remaining 1,850 articles, 983 articles were eliminated because of review or case report, or summary of treating experience or animal studies. For a further step, we excluded 812 studies by reason that they not used FSZR, or used any other TCM, or not real RCTs. Fifty-five RCTs were left and evaluated by the Cochrane risk of bias tool. Among which, 13 studies (Zhou et al., [@B73]; Lian et al., [@B37]; Li et al., [@B36]; Liu and Nan, [@B39]; Jiang, [@B25]; Long, [@B40]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Lu, [@B41]; Pan, [@B47]; Wang et al., [@B59]; Yuan et al., [@B69]; Shi et al., [@B54]) were assessed in RCTs with a cumulative score of at least 4 out of 7 for the Cochrane risk of bias tool domains and were ultimately included. The screening process is summarized in a flow diagram (Figure [1](#F1){ref-type="fig"}).

![Flowchart of study screening. FSZR, Chinese formulae that contains suanzaoren. TCM, Traditional Chinese medicine; RCTs, randomized controlled trials.](fphar-09-00076-g0001){#F1}

Study characteristics
---------------------

Characteristic of included studies was showed in Table [1](#T1){ref-type="table"}. All involved articles were published in Chinese language. All 13 trials were RCTs, and the sample size ranged from 33 to 366, mean aged 26.42 to 71.9 years. The disease durations before treatment lasted from 39 days to 7.9 years. The duration of treatment ranged from 15 days to 12 weeks. Five studies (Zhou et al., [@B73]; Lian et al., [@B37]; Jiang, [@B25]; Yuan et al., [@B69]; Shi et al., [@B54]) reported the follow-up time, which lasted from 1 week to 12 weeks. Twelve studies (Lian et al., [@B37]; Li et al., [@B36]; Liu and Nan, [@B39]; Jiang, [@B25]; Long, [@B40]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Lu, [@B41]; Pan, [@B47]; Wang et al., [@B59]; Yuan et al., [@B69]; Shi et al., [@B54]) reported the PSQI score and three studies (Li et al., [@B36]; Long, [@B40]; Wang et al., [@B59]) reported the PSG. The high-frequency herbs in the 13 included articles were detailed in Table [2](#T2){ref-type="table"}. The top 6 most frequently used herbs were Spine date seed *(Semen Ziziphi Spinosae*), Indian buead (*Indian buead)*, tuber fleeceflower stem (*Caulis Polygoni Multiflori*), debark peony root (*Radix Paeoniae Alba*), milkwort root (*Radix Polygalae*), Chinese angelica (*Radix Angelicae Sinensis*), which were used more than 3 times. The dose of SZR in each FSZR constituents varied from 24 to 36 g per day (Li et al., [@B36]; Jiang, [@B25]; Long, [@B40]; Pan, [@B47]). The ingredients and the usage of FSZR formulae were detailed in Table [3](#T3){ref-type="table"}. The sleep time was evaluated by Polysomnograghy or electroencephalogram in three studies (Li et al., [@B36]; Long, [@B40]; Wang et al., [@B59]) and PSQI scores in 12 studies (Lian et al., [@B37]; Li et al., [@B36]; Liu and Nan, [@B39]; Jiang, [@B25]; Long, [@B40]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Lu, [@B41]; Pan, [@B47]; Wang et al., [@B59]; Yuan et al., [@B69]; Shi et al., [@B54]). We have detailed the data in the Table [4](#T4){ref-type="table"}.

###### 

Characteristics of the included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Included trials**                           **Eligibility criteria**   **Country**   **Study design**   **No. of Participants(female)**   **Mean age (y)**   **Disease duration before treatment**   **Intervention drugs**   **Course of treatment**   **Outcomes**      **Intergroupdifference**   **Follow-up**                                                                                                      
  --------------------------- ----------------- -------------------------- ------------- ------------------ --------------------------------- ------------------ --------------------------------------- ------------------------ ------------------------- ----------------- -------------------------- ------------------------- ---------------------------------------------- ---------------------- ------------------ ------
  Shi et al., [@B54]          CCMD-3            China                      RCT           100(45)            100(59)                           26.42 ± 2.51       26.84 ± 3.69                            15.31 ± 0.85 (m)         14.23 ± 0.59 (m)          TYS               ES                         12w                       1\. PSQI SRSS\                                 1\. *P* \< 0.01\       12w                
                                                                                                                                                                                                                                                                                                                                   2. 5-HIAA; 5-HT; NA\                           2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. Clinical efficacy\                          3. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   4. Adverse events                                                                        

  Yuan et al., [@B69]         CCMD-3            China                      RCT           30(23)             30(26)                            39.57 ± 12.38      34.53 ± 11.73                           2.18 ± 2.08 (y)          2.18 ± 1.98 (y)           MA+ES             MAplacebo +ES              2w                        1\. PSQI total score\                          1\. *P* \< 0.01\       1w                 
                                                                                                                                                                                                                                                                                                                                   2. PSQI each factor score\                     2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. Clinical efficacy\                          3. *P* \< 0.01\                           
                                                                                                                                                                                                                                                                                                                                   4. TCM symptom\                                4. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   5. Adverse events                                                                        

  Pan, [@B47]                 GCTNPCM           China                      RCT           32(18)             32(14)                            39.6 ± 11.1        38.1 ± 9.2                              8.9 ± 2.6 (m)            8.2 ± 2.8 (m)             FFAM              ES                         4w                        1\. PSQI\                                      1\. *P* \< 0.05\       N.R.               
                                                                                                                                                                                                                                                                                                                                   2. Clinical efficacy\                          2. N.R.\                                  
                                                                                                                                                                                                                                                                                                                                   3. TCM symptom\                                3. P\>0.05\                               
                                                                                                                                                                                                                                                                                                                                   4. Sleep improving\                            4. P\>0.05                                
                                                                                                                                                                                                                                                                                                                                   5. Adverse events                                                                        

  Jing, [@B27]                CCMD-3R           China                      RCT           21(17)             26(18)                            41.82 ± 12.88      42.37 ± 11.64                           7.9 ± 3.84 (y)           5.7 ± 2.53 (y)            XSN               Placebo                    3w                        1\. PSQI\                                      1\. *P* \< 0.01\       N.R.               
                                                                                                                                                                                                                                                                                                                                   2. Clinical efficacy\                          2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. TCM symptom\                                3. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   4. SAS**;** SDS\                               4. *P* \> 0.05\                           
                                                                                                                                                                                                                                                                                                                                   5. Reducing rate of ES 6. Adverse events       5. N.R.                                   

  Jiang, [@B25]               CCMD-2-R          China                      RCT           183(93)            183(95)                           71.9               70.8                                    33.1 ± 5.7 (m)           31.4 ± 7.1 (m)            FZZR              AP                         3w                        1\. PSQI\                                      1\. *P* \< 0.05\       1m                 
                                                                                                                                                                                                                                                                                                                                   2. Clinical efficacy\                          2. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   3. Adverse events                                                                        

  Long, [@B40]                CCMD-3            China                      RCT           21(N.R.)           21(N.R.)                          45.95 ± 10.72      47.57 ± 10.67                           N.R.                     N.R.                      BBZH              Oryzanol                   2w                        1\. PSQI\                                      1\. P1 \< 0.05\        N.R.               
                                                                                                                                                                                                                                                                                                                                   2. PSG index\                                  2. N.R.\                                  
                                                                                                                                                                                                                                                                                                                                   3. TCM symptom\                                3. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   4. Adverse events                                                                        

  Liu and Nan, [@B39]         TCM vs. WM        ICSD                       China         RCT                30(18)                            30(17)             36.9 ± 11.48                            37.2 ± 11.36             8.9 ± 2.84 (m)            9.3 ± 2.18 (m)    ZRAS                       ES                        3w                                             1\. PSQI\              1\. *P* \< 0.05\   N.R.
                                                                                                                                                                                                                                                                                                                                                                                  2. Clinical efficacy   2. P\>0.05         

                              TCM vs. placebo   ICSD                       China         RCT                30(18)                            30(17)             36.9 ± 11.48                            37.8 ± 11.38             8.9 ± 2.84 (m)            9.8 ± 2.28 (m)    ZRAS                       placebo                   3w                                             1\. PSQI\              1\. *P* \< 0.05\   N.R.
                                                                                                                                                                                                                                                                                                                                                                                  3. Clinical efficacy   3. *P* \< 0.05     

  Li et al., [@B36]           TCM vs. WM        ICSD-2                     China         RCT                9(8)                              5(3)               38.4 ± 13.8                             37.6 ± 10.3              51.1 ± 32.9 (d)           39.0 ± 37.7 (d)   JWXY+ESplacebo             ES+JWXY placebo           6w                                             1\. PSQI; SRSS\        1\. N.R.\          N.R.
                                                                                                                                                                                                                                                                                                                                                                                  2. PSG index           2. N.R.            

                              TCM vs. placebo   ICSD-2                     China         RCT                9(8)                              10(6)              38.4 ± 13.8                             30.0 ± 9.7               51.1 ± 32.9 (d)           47.7 ± 33.2 (d)   JWXY +ESplacebo            JWXY placebo +ESplacebo   6w                                             1\. PSQI; SRSS\        1\. N.R.\          N.R.
                                                                                                                                                                                                                                                                                                                                                                                  2. PSG index           2. N.R.            

  Zhou et al., [@B73]         CCMD-2-R          China                      RCT           58(N.R.)           62(N.R.)                          N.R.               N.R.                                    N.R.                     N.R.                      SA                ES                         15d                       1\. SDRS\                                      1\. *P* \< 0.001\      1w                 
                                                                                                                                                                                                                                                                                                                                   2. HAMA\                                       2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. CGI-SI\                                     3. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   4. Adverse events                                                                        

  Lian et al., [@B37]         CCMD-3            China                      RCT           71(48)             36(20)                            43.14 ± 13.91      44.73 ± 13.92                           19.83 ± 27.13 (m)        20.92 ± 45.12 (m)         CYAS              Placebo                    3w                        1\. sleep-score\                               1\. *P* \< 0.01\       1w                 
                                                                                                                                                                                                                                                                                                                                   2. PSQI\                                       2. *P* \< 0.01\                           
                                                                                                                                                                                                                                                                                                                                   3. total sleep time\                           3. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   4. TCM symptom\                                4. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   5. Clinical effective rate 6. Adverse events   5. N.R.                                   

  Lu, [@B41]                  CCMD-3            China                      RCT           36(20)             12(7)                             18-65              18-65                                   1-12(m)                  1-12(m)                   QXZS              Placebo                    4w                        1\. PSQI\                                      1\. *P* \< 0.05\       N.R.               
                                                                                                                                                                                                                                                                                                                                   2. Clinical efficacy\                          2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. TCM symptom\                                3.*P* \> 0.05                             
                                                                                                                                                                                                                                                                                                                                   4. Adverse event                                                                         

  Wang Z. T. et al., [@B60]   CCMD-3            China                      RCT           41(N.R.)           39(N.R.)                          N.R.               N.R.                                    N.R.                     N.R.                      SQ                Placebo                    4w                        1\. PSQI total score\                          1\. *P* \< 0.05\       N.R.               
                                                                                                                                                                                                                                                                                                                                   2. PSQI each factor score\                     2. *P* \< 0.05                            
                                                                                                                                                                                                                                                                                                                                   3. Adverse event                                                                         

  Wang et al., [@B59]         CCMD-3            China                      RCT           48(30)             48(32)                            45.12 ± 11.51      44.58 ± 12.17                           27.16 ± 35.05(m)         25.99 ± 32.17 (m)         ZRAS              Placebo                    4w                        1\. PSQI\                                      1\. *P* \< 0.05\       N.R.               
                                                                                                                                                                                                                                                                                                                                   2. PSG\                                        2. *P* \< 0.05\                           
                                                                                                                                                                                                                                                                                                                                   3. TCM symptom\                                3.*P* \< 0.05                             
                                                                                                                                                                                                                                                                                                                                   4. Adverse event                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*CCMD, Chinese classification and diagnostic criteria for mental disorders; GCTNPCM, Guideline for Clinical Trials of New Patent Chinese Medicines; ICSD, International classification of sleep disorders; RCT, Randomized controlled trail; N.R., Not reported; y, Year; m, Month; w, Week; d, Day; TYS, Tangyushu powder preparation; ES, Estazolam tablet; MA, Mei\'an capsule; FFAM, Fufanganmei decoction; XSN, Xinshenning tablet; FZZR, Fuzhazaoren decoction; AP, Alprazolam tablet; BBZH, Banbaizhenhun decoction; ZRAS, Zaoren\'anshen tablet; JWXY, JiaweiXiaoyao powder; SA, Shen\'an 3 capsule; CYAS, Chanyeanshen capsule; QXZS, Qingxinzishui capsule; SQ, Sanqi granule; PSQI, Pittsburgh Sleep Quality Index; PSG, Polysomnograghy; SRSS, Self-rating scale of sleep; TCM, Traditional Chinese medicine; SAS, Self-rating depression scale; SDS, Self-rating anxiety scale; SDRS, Sleep dysfunction rating scale; HAMA, Hamilton anxiety scale; CGI, Clinical general impression scale; P, The significant difference between experimental and control group*.

###### 

Analysis of the high frequency herbs in treatment of insomnia.

  **Chinese name**   **Common name**              **Latin name**                  **Frequency**
  ------------------ ---------------------------- ------------------------------- ---------------
  Suanzaoren         Spine date seed              *Semen ZiziphiSpinosae*         13
  Fuling             Indian buead                 *Indian buead*                  4
  Shouwuteng         tuber fleeceflower stem      *Caulis PolygoniMultiflori*     4
  Baishao            debark peony root            *Radix Paeoniae Alba*           4
  Yuanzhi            milkwort root                *Radix Polygalae*               3
  Danggui            Chinese angelica             *Radix AngelicaeSinensis*       3
  Shichangpu         grassleafsweetflag rhizome   *RhizomaAcoriTatarinowii*       2
  Baihe              lily bulb                    *BulbusLilii*                   2
  Chaihu             Chinese thorowax root        *Radix Bupleuri*                2
  Huanglian          golden thread                *RhizomaCoptidis*               2
  Zhenzhumu          nacre                        *Concha Margaritifera*          2
  Banxia             pinellia tuber               *RhizomaPinelliae*              2
  Longchi            Dragon\'s Teeth              *Mastodifossiliadentis*         2
  Chenpi             dried tangerine peel         *PericarpiumCitriReticulatae*   2

###### 

Ingredients and usage of FSZR formulae.

  **Included studies**        **Prescription**   **Constitution**                                                                                                                                                                                                                                                                                          **Usage**          **Preparations**
  --------------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------
  Shi et al., [@B54]          TYS                Semen ZiziphiSpinosae, RhizomaCoptidis, PericarpiumCitriReticulatae, Caulis Bambusae in Taenia, RhizomaAcoriTatarinowii, Radix Polygalaea                                                                                                                                                                 15 g tidpo         Power
  Yuan et al., [@B69]         MA+ES              Semen ZiziphiSpinosae, Radix Ginseng, Eleutherococcussenticosus, Indian buead, Radix AngelicaeSinensis, RhizomaLigusticiChuanxionga                                                                                                                                                                       4 g qnpo           Granule
  Pan, [@B47]                 FFAM               Semen ZiziphiSpinosae 12 g, OsDraconis 9 g, Concha Margaritifera 9 g, Caulis PolygoniMultiflori 12 g, FructusSchisandraeChinensis 3 g, Radix Paeoniae Alba 9 g, Radix RehmanniaeRecens 9 g                                                                                                                One dose bid po    Decoction
  Jing, [@B27]                XSN                Semen ZiziphiSpinosae, Indian buead, Caulis PolygoniMultiflori, Massa MedicataFermentata, FructusGardeniaea                                                                                                                                                                                               4 g tidpo          Tablet
  Jiang, [@B25]               FZZR               Semen ZiziphiSpinosae 15 g, Indian buead 12 g, FructusCrataegi 15 g                                                                                                                                                                                                                                       One dose bid po    Decoction
  Long, [@B40]                BBZH               Semen ZiziphiSpinosae 30 g, RhizomaPinelliae 10 g, BulbusLilii30 g, Radix Curcumae 10 g, Caulis PolygoniMultiflori 30 g, Magnetitum 30 g, Concha Ostreae 30 g, Mastodifossiliadentis 30 g, Concha Margaritifera 30 g, Indian buead 15 g, PericarpiumCitriReticulatae 10 g, RhizomaAcoriTatarinowii 10 g   Half dose bid po   Decoction
  Liu and Nan, [@B39]         ZRAS               Semen ZiziphiSpinosae, Radix SalviaeMiltiorrhizae, FructusSchisandraeChinensisa                                                                                                                                                                                                                           5 \# qnpo          Tablet
  Li et al., [@B36]           JWXY               Semen ZiziphiSpinosae 18 g, Poria cum Radix Pini 15 g, Radix Bupleuri 9 g, Radix AngelicaeSinensis 10 g, Radix Paeoniae Alba 15 g, RhizomaAtractylodisMacrocephalae 12 g, Radix Glycyrrhizae 5 g, HerbaMenthae 5 g, RhizomaZingiberisRecens 4 g                                                           250ml bid po       Power
  Zhou et al., [@B73]         SA                 Ganoderma, BulbusLilii, Radix PaeoniaeRubra, Radix SalviaeMiltiorrhizae, Cortex MoutanRadicis, Semen ZiziphiSpinosae, Radix Pseudostellariae, Mastodifossiliadentis, Succinuma                                                                                                                            5 \# qnpo          Capsule
  Lian et al., [@B37]         CYAS               Semen ZiziphiSpinosae, Periostracum Cicadae, Caulis PolygoniMultiflori, BombyxBatryticatus, Lumbricus, Radix Paeoniae Alba, RamulusUncariae Cum Uncis, RhizomaPinelliae, Radix Polygalaea                                                                                                                 5\# qnpo           Capsule
  Lu, [@B41]                  QXZS               Semen ZiziphiSpinosaea, RhizomaCoptidis, Radix Scutellariae, Radix Paeoniae Alba, CollaCoriiAsini, Cortex Cinnamomi, Cortex Albiziae                                                                                                                                                                      5 \# tidpo         Capsule
  Wang Z. T. et al., [@B60]   SQ                 Semen ZiziphiSpinosae, Caulis Spatholobi, Radix Notoginseng, Cirsiumjaponicuma                                                                                                                                                                                                                            One dose qdpo      Granule
  Wang et al., [@B59]         ZRAS               Semen ZiziphiSpinosae, Caulis PolygoniMultiflori, Fructus Mori, FlosAlbiziae, Semen Platycladi, Radix AngelicaeSinensis, Radix RehmanniaePreparata, Radix Polygalae, Radix Bupleuria                                                                                                                      4 \# tidpo         Tablet

*TYS, Tangyushu powder preparation; MA, Mei\'ancapsule; FFAM, Fufanganmeidecoction; XSN, Xinshenning tablet; FZZR, Fuzhazaoren decoction; BBZH, Banbaizhenhun decoction; ZRAS, Zaoren\'anshen tablet; JWXY, JiaweiXiaoyao powder; SA, Shen\'an 3 capsule; CYAS, Chanyeanshen capsule; QXZS, Qingxinzishui capsule; SQ, Sanqi granule; bid, bis in die; d:day; po, peros; qd, quaquedie; tid, ter in die; w, week; \#, tablet*.

###### 

Characteristics of the Sleeping time of included studies.

  **Included trials**         **Methods**       **Sleeping-time (before)**   **Sleeping-time (after)**                                         
  --------------------------- ----------------- ---------------------------- --------------------------- ----------------- ------------------- -----------------
  Shi et al., [@B54]          PSQI              NG                           NG                          NG                NG                  
  Yuan et al., [@B69]         PSQI              1.53 ± 1.07                  1.53 ± 0.97                 1.10 ± 0.88       1.33 ± 0.96         
  Pan, [@B47]                 PSQI              2.58 ± 1.01                  2.46 ± 0.93                 1.05 ± 0.99       1.71 ± 0.86         
  Jing, [@B27]                PSQI              NG                           NG                          NG                NG                  
  Jiang, [@B25]               PSQI              2.7 ± 0.5                    2.7 ± 0.7                   0.6 ± 0.7         1.2 ± 0.7           
  Long, [@B40]                PSG(m)            360.60 ± 32.975              355.76 ± 30.363             368.07 ± 32.794   358.71 ± 34.229     
  Liu and Nan, [@B39]         TCM vs. WM        PSQI                         NG                          NG                NG                  NG
                              TCM vs. placebo   PSQI                         NG                          NG                NG                  NG
  Li et al., [@B36]           TCM vs. WM        PSG(m) PSQI                  367.5 ± 52.0 NG             405.7 ± 38.2 NG   391.8 ± 44.5 NG     378.6 ± 53.9 NG
                              TCM vs. placebo   PSG(m) PSQI                  367.5 ± 52.0 NG             385.8 ± 43.4 NG   391.8 ± 44.5 NG     405.6 ± 49.4 NG
  Zhou et al., [@B73]         PSQI              NG                           NG                          NG                NG                  
  Lian et al., [@B37]         PSQI              4.91 ± 0.87                  4.55 ± 1.06                 6.29 ± 1.17       5.22 ± 1.16         
  Lu, [@B41]                  PSQI              2.39 ± 0.68                  2.49 ± 0.69                 1.12 ± 0.67       2.32 ± 0.72         
  Wang Z. T. et al., [@B60]   PSQI              4.32 ± 1.56                  4.18 ± 1.81                 5.77 ± 1.47       4.87 ± 1.99         
  Wang et al., [@B59]         PSG(m) PSQI       339.66 ± 77.1 NG             368.90 ± 70.12 NG           388.26 ± 74 NG    367.93 ± 86.07 NG   

*N.G., Not given; w, Week; m, minite; TYS, Tangyushu powder preparation; ES, Estazolam tablet; MA, Mei\'an capsule; FFAM, Fufanganmei decoction; XSN, Xinshenning tablet; FZZR, Fuzhazaoren decoction; AP, Alprazolam tablet; BBZH, Banbaizhenhun decoction; ZRAS, Zaoren\'anshen tablet; JWXY, JiaweiXiaoyao powder; SA, Shen\'an 3 capsule; CYAS, Chanyeanshen capsule; QXZS, Qingxinzishui capsule; SQ, Sanqi granule; PSQI, Pittsburgh Sleep Quality Index; PSG, Polysomnograghy; P, The significant difference between experimental and control group*.

Risk of bias within studies
---------------------------

The Cochrane\'s risk of bias score of included studies ranged from 4 to 7 (Table [5](#T5){ref-type="table"}). All of the retrieved articles belonged to RCT. Among which, 11 out of 13 articles described the method of random sequences generation. Four studies (Lian et al., [@B37]; Li et al., [@B36]; Pan, [@B47]; Yuan et al., [@B69]) implemented the concealment allocation. The blinding was used in 11 studies except two studies (Pan, [@B47]; Shi et al., [@B54]), including seven double blinding (Zhou et al., [@B73]; Lian et al., [@B37]; Li et al., [@B36]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Wang et al., [@B59]; Yuan et al., [@B69]) and four single blinding (Liu and Nan, [@B39]; Jiang, [@B25]; Long, [@B40]; Lu, [@B41]). There were five studies (Lian et al., [@B37]; Li et al., [@B36]; Jing, [@B27]; Wang et al., [@B59]; Yuan et al., [@B69]) described the blinding procedure. Three studies (Li et al., [@B36]; Yuan et al., [@B69]; Shi et al., [@B54]) avoided the detection bias by blind the statisticians. Selection bias and other bias were not found in all included studies.

###### 

The methodological quality of included studies.

                              **A**   **B**   **C**   **D**   **E**   **F**   **G**   **Total score**
  --------------------------- ------- ------- ------- ------- ------- ------- ------- -----------------
  Shi et al., [@B54]          \+      ?       ?       \+      \+      \+      \+      5+
  Yuan et al., [@B69]         \+      \+      \+      \+      \+      \+      \+      7+
  Pan, [@B47]                 \+      \+      ?       \+      ?       \+      \+      5+
  Jing, [@B27]                \+      ?       \+      \+      ?       \+      \+      5+
  Jiang, [@B25]               \+      ?       \+      \+      ?       \+      \+      5+
  Long, [@B40]                \+      ?       \+      \+      ?       \+      \+      5+
  Liu and Nan, [@B39]         \+      ?       \+      \+      ?       \+      \+      5+
  Li et al., [@B36]           \+      \+      \+      \+      \+      \+      \+      7+
  Zhou et al., [@B73]         \+      ?       \+      \+      ?       \+      \+      5+
  Lian et al., [@B37]         \+      \+      \+      \+      ?       \+      \+      6+
  Lu, [@B41]                  ?       ?       \+      \+      ?       \+      \+      4+
  Wang Z. T. et al., [@B60]   \+      ?       \+      \+      ?       \+      \+      5+
  Wang et al., [@B59]         ?       ?       \+      \+      ?       \+      \+      4+

*A, random sequence generation; B, allocation concealment; C, blinding of participants and personnel; D, blinding of outcome assessment; E, imcomplete outcome data; F, selective reporting; G, other sources of bias*.

Effectiveness
-------------

### FSZR vs. placebo

There were six studies (Lian et al., [@B37]; Liu and Nan, [@B39]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Lu, [@B41]; Wang et al., [@B59]) comparing FSZR with placebo for treating insomnia (Table [1](#T1){ref-type="table"}). Meta-analysis of above six studies showed significant between-group difference in PSQI scores (*n* = 438, SMD = −1.05, 95% CI: −1.49 to −0.60, *P* \< 0.00001, heterogeneity X^2^ = 23.36, df = 5, *P* = 0.004, *I*^2^ = 74%). After removing study by Lu et al. (Lu, [@B41]) that was considered the potential sources of the heterogeneity because of small sample size, meta-analysis of five studies (Lian et al., [@B37]; Liu and Nan, [@B39]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Wang et al., [@B59]) showed that FSZR better reduce the PSQI score than that of placebo in PSQI scores (*n* = 390, SMD = −0.82, 95% CI: −1.03 to −0.61, *P* \< 0.00001, heterogeneity X^2^ = 6.24, df = 4, *P* = 0.18, *I*^2^ = 36%; Figure [2](#F2){ref-type="fig"}). Meta-analysis of four studies (Lian et al., [@B37]; Liu and Nan, [@B39]; Jing, [@B27]; Lu, [@B41]) found significant difference in clinical effective rate between the FSZR and placebo groups (*n* = 256, RR: 1.73, 95% CI 1.25 to 2.39, *P* = 0.0009, heterogeneity X^2^ = 6.59, df = 3, *P* = 0.09, *I*^2^ = 54%). After removing study by Liu et al. (Liu and Nan, [@B39]) whose diagnostic criteria differed from other three studies, meta-analysis of three studies (Lian et al., [@B37]; Jing, [@B27]; Lu, [@B41]) showed that FSZR was significantly more effective than that of placebo in clinical effective rate (*n* = 196, RR: 2.04, 95% CI 1.52 to 2.74, *P* \< 0.00001, heterogeneity X^2^ = 0.14, df = 2, *P* = 0.93, *I*^2^ = 0%; Figure [3](#F3){ref-type="fig"}).

![PSQI scores of FSZR vs. placebo. PSQI, Pittsburgh Sleep Quality Index; FSZR, Chinese formulae that contains suanzaoren.](fphar-09-00076-g0002){#F2}

![Clinical effective rate of FSZR vs. placebo. FSZR, Chinese formulae that contains suanzaoren.](fphar-09-00076-g0003){#F3}

### FSZR vs. diazepam

Five studies (Zhou et al., [@B73]; Liu and Nan, [@B39]; Jiang, [@B25]; Pan, [@B47]; Shi et al., [@B54]) investigated FSZR vs. Diazepam. The meta-analysis was not conducted because of high heterogeneity. Three studies (Jiang, [@B25]; Pan, [@B47]; Shi et al., [@B54]) found that FSZR was more effective than Diazepam in PSQI score (*P* \> 0.05), whereas one study (Liu and Nan, [@B39]) showed no significant difference. FSZR was significantly improving clinical effective rate in two studies (Jiang, [@B25]; Shi et al., [@B54]) (*P* \< 0.05), but not in other two studies (Liu and Nan, [@B39]; Pan, [@B47]) (*P* \> 0.05) relative to Diazepam.

### FSZR plus diazepam vs. FSZR placebo plus diazepam

Two studies (Li et al., [@B36]; Yuan et al., [@B69]) compared FSZR plus Diazepam with FSZR placebo plus Diazepam. Meta-analysis showed a significant reduction in PSQI scores for the combination therapy relative to estazolam alone (*n* = 74, SMD = −0.53, 95% CI: −1.00 to −0.06, *P* = 0.03, heterogeneity X^2^ = 1.87, df = 1, *P* = 0.17, *I*^2^ = 47%) (Figure [4](#F4){ref-type="fig"}). The study by Yuan et al. ([@B69]) found FSZR was significantly more effective than placebo in clinical effective rate (*P* \< 0.05).

![PSQI scores of FSZR plus Diazepam vs. FSZR placebo plus Diazepam. PSQI, Pittsburgh Sleep Quality Index; FSZR, Chinese formulae that contains suanzaoren.](fphar-09-00076-g0004){#F4}

Adverse events
--------------

Twelve out of 13 studies reported adverse events. One study (Shi et al., [@B54]) reported adverse events in both experimental group and control group, including acratia, somnolence, dizzy, diarrhea, and dry mouth. Two studies (Zhou et al., [@B73]; Jiang, [@B25]) reported side effects in control group alone, including dry mouth, constipation, nausea, somnolence, dizzy, fatigued, and memory decline. Serious and life-threatening adverse events, such as an irregular heartbeat, seizures, and death were not happened in all included studies.

Mechanisms of SZR for insomnia
------------------------------

SZR exerts a range of sedative and hypnotic actions mediated primarily by the GABAergic and serotonergic system (Ma et al., [@B42]; Wang L. E. et al., [@B58]; Shergis et al., [@B53]) (Figure [5](#F5){ref-type="fig"}). The SZR typically contains complex mixtures of phytochemicals, including sanjoinine A, Jujuboside A (JuA), spinosin and other flavonoids (Yang et al., [@B64]). Sanjoinine A, one of the aporphine alkaloid from SZR, was demonstrated to enhance sleep behaviors and augment pentobarbital-induced sleeping behaviors through GABAergic system (Han et al., [@B21]; Rodríguez and Rodríguez, [@B50]). Furthermore, Sanjoinine A increases chloride influx and GABA synthesis via glutamic acid decarboxylase (GAD 65/67) activation in cultured cerebellar granule cells, inducing prolonged sleeping time (Zhang et al., [@B70]). JuA inhibits the rat hippocampus excitatory state *in vivo* and *in vitro* through glutamate-mediated excitatory signal pathway (Cao et al., [@B8]), affecting GABAergic and serotonergic system. Low dose of JuA exerts sedative-hypnotic effects related to increasing the GABAA receptor (α1, α5, ß2) gene expression (You et al., [@B68]). Flavonoids in the water extract of SZR also contribute to insomnia treatment. The flavonoid 6-hydroxyflavone is involved in the binding of GABAA receptors showing partial agonistic action (Ren et al., [@B49]). The administration of spinosin, a C-glycoside flavonoid, showed significant sedative effects at increasing total sleep time and reducing sleep latency in pentobarbital treated rat group (Lee et al., [@B29]).

![The mechanism of sedative-hypnotic effect in SZR for insomnia. SZR, suanzaoren; GABA, gamma-aminobutyric acid; 5-HT~1A~, 5-hydroxytryptamine (1A); JuA, Jujuboside A; Solid lines indicate established effects, whereas dashed lines represent putative mechanism.](fphar-09-00076-g0005){#F5}

The quality of the evidence
---------------------------

Summary of Findings (SOF) tables were provided by the GRADE profiler. The quality of the evidence was high or moderate according to the GRADE assessment, we summarized the result in Table [6](#T6){ref-type="table"}.

###### 

Quality of evidence by GRADE system.

  **Quality assessment**                                                  **Risk of bias**   **Inconsistency**   **Indirectness**   **Imprecision**   **Other considerations**   **No. of patients**   **Quality**   **Importance**              
  ----------------------------------------------------------------------- ------------------ ------------------- ------------------ ----------------- -------------------------- --------------------- ------------- ---------------- ---------- ----------
  **PSQI (FOLLOW-UP MEAN 3.4 WEEKS; BETTER INDICATED BY LOWER VALUES)**                                                                                                                                                                          
  5                                                                       RCTs               Serious             No serious         No serious        No serious                 none                  211           179              Moderate   Critical
                                                                                                                 inconsistency      indirectness      imprecision                                                                                
  **CLINICAL EFFECTIVE RATE (FOLLOW-UP MEAN 3.3 WEEKS)**                                                                                                                                                                                         
  3                                                                       RCTs               Serious             No serious         No serious        No serious                 Strong                128           74               High       Critical
                                                                                                                 inconsistency      indirectness      imprecision                association                                                     

*RCT: randomized controlled trial; PSQI, Pittsburgh Sleep Quality Index; FSZR, Chinese formulaethat contains Suanzaoren*.

Discussion {#s4}
==========

Summary of main findings
------------------------

Our previous system review (Xie et al., [@B62]) showed that the current evidence was insufficient to support the efficacy and safety of SZRD for insomnia due to lack of high-quality RCTs. The present study is an updated systematic review based on the high-quality RCTs. Thirteen studies with 1,454 individuals were identified in analysis. The findings demonstrated that FSZR used as a monotherapy was superior to placebo and as an adjunct therapy was superior to Diazepam alone in terms of PSQI score and clinical effective rate, whereas there were mixed results comparing FSZR with Diazepam directly. There were fewer adverse effects in comparison with controls and no life-threatening side effects were happened in all included studies. The quality of the evidence was high or moderate based on the updated GRADE methodology and profiler.

Limitations {#s5}
===========

The strength of this study was that all studies included had low risk of bias with positive for at least four out of seven for the Cochrane risk of bias domains. However, we did acknowledge that there were some methodological limitations which were worth noting. Firstly, allocation concealment was used in two studies (Ma et al., [@B42]; Moher et al., [@B43]). The trials with inadequate or unclear concealment of allocation were about 18% more "beneficial" than that with adequate concealment (95% CI 5% to 29%; Higgins and Green, [@B23]). Secondly, blinding was an essential method to limit the occurrence of performance bias and ascertainment bias in clinical trials (Health Canada, [@B22]). Although there were 11 out of 13 studies that mentioned the blinding, double-blinding and placebo design was reported in six studies (Lian et al., [@B37]; Wang Z. T. et al., [@B60]; Jing, [@B27]; Lu, [@B41]; Wang et al., [@B59]; Yuan et al., [@B69]). One of the main reasons for not using double-blinded study was that the placebos of CHMs is difficult to prepared in the same color, flavor and taste. Thirdly, the follow-up period was not long enough to achieve crucial results because insomnia may wax and wane with or without treatment. Thus, a longer follow-up period was necessary (Xie et al., [@B62]). At least 6-month follow-up may assess whether a sustained effect and safety of FSZR for insomnia can persist for a long period (European Medicines Agency, [@B14]). Finally, the quality control of herbal preparations is crucial for the validity of the study results. However, only some patent FSZR mentioned in this important issue. Suanzaoren contains complex mixtures of phytochemicals such as sanjoinine A, Jujuboside A, spinosin, and other flavonoids, which can be further used for the marker of quality control of the herbal preparations.

Implication for practice
------------------------

This is an updated system review of high-quality RCTs to assess the efficacy and safety of FSZR for insomnia. In the present study, patients receiving FSZR monotherapy was superior to placebo, and equivalent to Diazepam. Combined FSZR with Diazepam was superior to Diazepam alone. Furthermore, FSZR caused fewer side effects than that of Diazepam. Therefore, FSZR therapy may be effective and well tolerated for the treatment of insomnia. Taken together, our findings supported that clinicians may option FSZR as an alternative treatment for insomnia.

Implication for research
------------------------

There are many implications arising from research. First, although double-blinding is encouraged in RCTs, it is inherently difficult in herbal placebo because of the specific color, flavor, and taste of CHMs (Ni et al., [@B46]). One of possible solutions is that herbs can be prepared as tablets or capsules to facilitate the development of a convincing placebo (Fu et al., [@B18]); however, the use of capsules is still challenged because of the change of efficacy and characteristics of drugs (Stegemann and Bornem, [@B56]). Second, SZR is the most frequently used herb for insomnia, and it is regarded as an essential constitute in numbers of classical herbal formulae (Li and Bi, [@B34]; Lei et al., [@B31]). In the present study, the most frequently used herbs were *Semen Ziziphi Spinosae, Indian buead, Caulis Polygoni Multiflori, Radix Paeoniae Alba, Radix Polygalae*, Radix Angelicae Sinensis, which is worth further carrying out rigor RCTs as candidate formula. Third, Sanjoinine A, JuA, and flavonoids in the water extract of SZR contributed to its sedative-hypnotic effects. The increasing of chloride influx and over-expression of α- and γ-subunit GABA receptor was involved in the mechanisms of these effects. The modification of serotonin and glutamate also inducing sleep, but the exact role of the regulation of sleep is still unknown. Further experimental studies are required to unravel the mechanisms of FSZR for insomnia.

Conclusion {#s6}
==========

In the present study, the findings demonstrated that FSZR therapy was effective and well tolerated for insomnia through sedative and hypnotic actions primarily mediated by the GABAergic and serotonergic system. Thus, FSZR could be an alternative treatment for insomnia in clinical practice.
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